Poor performance of D-Dimer in excluding venous thromboembolism among patients with lymphoma and leukemia

Aiham Qdaisat, Rawan Al Soud, Carol C. Wu, Cristhiam M. Rojas Hernandez, Jieli Li, Qing H. Meng, Hikmat Abdel-Razeq, and Sai-Ching Jim Yeung

Disclosures: Dr. Yeung is the principal investigator of an investigator-initiated clinical trial supported by DepoMed and a retrospective clinical study supported by Bristol-Myers Squibb through ARISTA-USA (BMS/Pfizer American Thrombosis Investigator Initiated Research Program). Dr. Yeung was a member of an Advisory Panel to Celgene Corporation. Dr. Rojas-Hernandez is an advisory bureau/preceptor for Bristol-Myers Squibb. Dr. Rojas-Hernandez has a funding for research through Daichii-Sankyo. All other authors declare no competing financial or non-financial interests. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Contributions: S-CJY and AQ conceived and designed the study and developed the methods. S-CJY and HA-R provided study supervision. AQ, JL, QHM acquired data from MD Anderson. RAS acquired data from King Hussain Cancer Center. CCW reviewed questionable diagnostic images. AQ analyzed and interpreted the data. S-CJY supervised statistical analysis. AQ created the figures and tables. AQ, RAS, CCW, CMRH, JL, QHM, HA-R, and S-CJY drafted the manuscript. All authors reviewed and provided final approval of the manuscript.